Please assess the completion status of the following clinical trial:

Trial Title: Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Male and female participants between 21-60 years of age.~Good health as determined by medical history, physical exam, ECG and lab tests.~Creatinine less than to 2 mg/dl.~Female must have a negative urine pregnancy (hCG) test at the start of each study session. Females of childbearing potential who are sexually active and have not been surgically sterilized must agree to use an adequate method of birth control during the study. Adequate methods of contraception for sexually active women are having a male sexual partner(s) who is surgically sterilized prior to inclusion; having a sexual partner(s) who is/are exclusively female; using oral contraceptives (either combined or progestrogen only) with a single-barrier method of contraception consisting of spermicide and condom or diaphragm; using double-barrier contraception, specifically, a condom plus spermicide and a female diaphragm or cervical cap plus spermicide; or using an approved intrauterine device (IUD) with established efficacy.~Participants must drink alcohol regularly at a heavy level, on average greater than 20 drinks per week for men, and greater than 15 drinks per week for women, and not be seeking help for alcohol-related problems.~Participant must be willing to receive two IV lines.~EXCLUSION CRITERIA:~Current or prior history of any clinically significant disease, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders.~Specific exclusion criteria related to the administration of ghrelin, are chronic inflammatory diseases (e.g., Crohn s disease, ulcerative colitis, celiac disease) diabetes, obesity (BMI greater than or equal 30 kg/m(2), weight greater than or equal to 120 Kg, high triglycerides level (\> 350 mg/dL), history of clinically significant hypotension (e.g.: history of fainting and/or syncopal attacks) and/or resting systolic BP \< 100 mmHg.~Positive hepatitis or HIV test at screening.~Current clinically significant major depression or anxiety; or prior clinically significant psychiatric problems, including eating disorders, schizophrenia, bipolar disorder, obsessive compulsive disorder.~Current diagnosis of substance dependence (other than alcohol or nicotine).~Currently seeking treatment for alcohol use disorder.~History of significant withdrawal symptoms or presence of clinically significant withdrawal symptoms (Clinical Institute Withdrawal Assessment (CIWA) score \> 8) at screening.~Non-drinkers (alcohol-naive individuals or current abstainers) or no experience drinking 5 or more drinks on one occasion.~Unable to provide a negative urine drug screen.~Pregnancy or intention to become pregnant for women. Female participants will undergo a urine beta-hCG test to ensure they are not pregnant.~Use of prescription or OTC medications known to interact with alcohol within 2 weeks of the study. These include, but may not be limited to: isosorbide, nitroglycerine, benzodiazepines, warfarin, anti-depressants such as amitriptyline, clomipramine and nefazodone, anti-diabetes medications such as glyburide, metformin and tolbutamide, H2-antagonists for heartburn such as cimetidine and ranitidine, muscle relaxants, anti-epileptics including phenytoin and Phenobarbital codeine, and narcotics including darvocet, percocet and hydrocodone. Drugs known to inhibit or induce enzymes that metabolize alcohol should not be used for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram. Cough-and-cold preparations, which contain antihistamines, pain medicines and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib and naproxen, should be withheld for at least 72 hours prior to each study session.~Current or prior history of alcohol-induced flushing reactions.~Contraindications for MRI scanning, including metal in body that are contraindicated for MRI (such as implants, pacemaker, prostheses, shrapnel, irremovable piercings), left-handedness, and claustrophobia.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- ASA/Ghrelin (Type: EXPERIMENTAL): Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the first ASA visit; Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the second ASA visit.
- ASA/Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the first ASA visit; Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the second ASA visit
- fMRI/Ghrelin (Type: EXPERIMENTAL): Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the first fMRI visit; Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the second fMRI visit.
- fMRI/Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo \[packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor\] was administered on the first fMRI visit; Intravenous acyl-ghrelin \[a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)\] was administered on the second fMRI visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete